Skip to main content

Table 1 Patient baseline characteristics

From: Response to anti-PD1 therapy with nivolumab in metastatic sarcomas

Factor No
Age
 Median 57
 Range 24–78
Sex
 Female 14
 Male 14
Soft tissue sarcoma 24
Bone sarcoma 4
Location
 Extremity 6
 Abdomen/pelvis 12
 Axial 2
 Head/neck 5
 Chest 3
Stage
 IV 26
 Unresectable 2
ECOG PS
 0–1 24
 2 4
Nivolumab  
 Cycles (median) 8
 Range 1–26
On Pazopanib 18
Prior treatments (including neoadjuvant/adjuvant)
 Median 2
 Range 0–6
 Anthracycline 15
 Ifosfamide 10
 Gemcitabine 9
 Docetaxel 7